An observational study in Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia and Chronic Myelogenous Leukemia, sponsored by Wake Forest University Health Sciences. Recruiting at 1 site in United States. Open to participants aged 18 Years to 120 Years. Per ClinicalTrials.gov, last updated 2026-04-13.
Sponsored by Wake Forest University Health Sciences · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 32 studies in Leukemia, Myeloid, Acute by Wake Forest University Health Sciences — 4 open to participants now, 5 under way, none of them phase 3. Leukemia, Myeloid, Acute · Wake Forest University Health Sciences.
Among the 32 studies in Leukemia, Myeloid, Acute by Wake Forest University Health Sciences, this one is the only one that started in 2001, is one of 5 observational ones, and was the 17th registered.
3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.
Browse Leukemia, Myeloid, Acute studies →4 of the 32 studies in Leukemia, Myeloid, Acute by Wake Forest University Health Sciences are open now, in 1 country. Recruiting first, the newest first:
Wake Forest University Health Sciences · Sites in United States
Ages 18–64
Wake Forest University Health Sciences · Sites in United States
Ages 18+
Wake Forest University Health Sciences · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.
This study: 18 Years to 120 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
32 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 8 · Phase 2 10 · Phase 3 1 · Phase 4 1
First in 2000; this study’s year is marked. 1 started in 2001.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 2,000 is above the median of 114 across 395 observational studies indexed under Leukemia, Myeloid, Acute.
Median enrollment 48 across the 25 interventional studies, 50 across the 5 observational. Of the 22 that completed or were terminated, 8 (36%) have results posted.
This tab as a report to print or save as PDF → With an account.
Wake Forest University Health Sciences is the lead sponsor of 1,353 studies on the registry; 199 are open to participants now.
Of its 332 completed or terminated interventional studies of FDA-regulated products, 251 (76%) have results posted.
3 of the studies in Leukemia, Myeloid, Acute by Wake Forest University Health Sciences that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT01890486Wake Forest University Health SciencesThe Prospective Collection, Storage and Reporting of Data on Patients Undergoing Hematopoietic Stem Cell Transplantation Utilizing a Standard Preparative Regimen | 2026-12 |
| NCT02835222Wake Forest University Health SciencesSelinexor With Combination With Induction/Consolidation Therapy in Acute Myeloid Leukemia Patients | 2027-04-18 |
| NCT06580106Wake Forest University Health SciencesToxicity Genetic Determinants and Response to Azacitidine and Venetoclax in AML | 2027-07 |
Add all 3 to your calendar (.ics) → With an account.
Among the 32 studies in Leukemia, Myeloid, Acute by Wake Forest University Health Sciences, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
To provide the IRB approved mechanism for the prospective collection and analysis on participants who are undergoing either an autologous or allogeneic hematopoietic stem cell transplant for a disease in which a research question is not being addressed.
To provide an IRB approved mechanism for the prospective collection and analysis on participants who are undergoing either an autologous or allogeneic hematopoietic stem cell transplant or cellular therapies for a disease in which a research question is not being addressed and for which peer reviewed, published data have demonstrated efficacy for this treatment approach.
To provide a consent mechanism for the retrospective study of cellular products, when available, if there is a specific question to be addressed.
Patients who are not on a specific "treatment research protocol" but who are nevertheless receiving "standard of care" dose intensive therapy and either an allogeneic or autologous bone marrow transplant
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Planned standard of care dose intensive therapy and either an or autologous bone marrow transplant
Exclusion Criteria:
Participation in any other treatment research protocol
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Allogeneic and autologous transplant
Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Data followup
Gather basic survival and complication data for operational and research databases for ongoing regulatory and future operational queries
Time frame: 1 year
Started May 2001 (actual). Primary completion is estimated for Dec 2026, 307 months after the start.
Of 128 non-industry observational studies under Leukemia, Myeloid, Acute, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 234. This study's planned 307 months is above that.
Counting every sponsor, half of 160 studies reached it within 54 months; a quarter within 35 and three quarters within 154.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Wake Forest University Health Sciences →